WO2021253376A1 - Preparation method for phosphamide compound used for synthesizing chiral drug - Google Patents
Preparation method for phosphamide compound used for synthesizing chiral drug Download PDFInfo
- Publication number
- WO2021253376A1 WO2021253376A1 PCT/CN2020/097026 CN2020097026W WO2021253376A1 WO 2021253376 A1 WO2021253376 A1 WO 2021253376A1 CN 2020097026 W CN2020097026 W CN 2020097026W WO 2021253376 A1 WO2021253376 A1 WO 2021253376A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- preparation
- compound
- stirring
- temperature
- compound used
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 239000003814 drug Substances 0.000 title abstract description 4
- 229940079593 drug Drugs 0.000 title abstract description 4
- -1 phosphamide compound Chemical class 0.000 title abstract description 3
- 230000002194 synthesizing effect Effects 0.000 title abstract description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 13
- 238000003756 stirring Methods 0.000 claims abstract description 12
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000007864 aqueous solution Substances 0.000 claims abstract description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims abstract description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 10
- 239000003513 alkali Substances 0.000 claims description 7
- 229960003767 alanine Drugs 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 abstract description 5
- 238000006243 chemical reaction Methods 0.000 abstract description 4
- 239000002904 solvent Substances 0.000 abstract description 4
- 239000007788 liquid Substances 0.000 abstract description 3
- 239000002699 waste material Substances 0.000 abstract description 2
- 238000004537 pulping Methods 0.000 abstract 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- XBNGYFFABRKICK-UHFFFAOYSA-N 2,3,4,5,6-pentafluorophenol Chemical compound OC1=C(F)C(F)=C(F)C(F)=C1F XBNGYFFABRKICK-UHFFFAOYSA-N 0.000 description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
- IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachloro-phenol Natural products OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 208000005176 Hepatitis C Diseases 0.000 description 4
- 238000010009 beating Methods 0.000 description 4
- 229960002063 sofosbuvir Drugs 0.000 description 4
- TTZHDVOVKQGIBA-IQWMDFIBSA-N sofosbuvir Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@]2(F)C)O)CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC=2C=CC=CC=2)C=CC(=O)NC1=O TTZHDVOVKQGIBA-IQWMDFIBSA-N 0.000 description 4
- 208000010710 hepatitis C virus infection Diseases 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- VTSRCHXIIMBAKT-WNQIDUERSA-N (2s)-2-aminopropanoic acid;2-chloropropane Chemical compound CC(C)Cl.C[C@H](N)C(O)=O VTSRCHXIIMBAKT-WNQIDUERSA-N 0.000 description 2
- 208000006154 Chronic hepatitis C Diseases 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- TXFOLHZMICYNRM-UHFFFAOYSA-N dichlorophosphoryloxybenzene Chemical compound ClP(Cl)(=O)OC1=CC=CC=C1 TXFOLHZMICYNRM-UHFFFAOYSA-N 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WSGYTJNNHPZFKR-UHFFFAOYSA-N 3-hydroxypropanenitrile Chemical compound OCCC#N WSGYTJNNHPZFKR-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229940126656 GS-4224 Drugs 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 241000097929 Porphyria Species 0.000 description 1
- 208000010642 Porphyrias Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 201000011200 hepatorenal syndrome Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- VRTWBAAJJOHBQU-KMWAZVGDSA-N ledipasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N([C@@H](C1)C=2NC(=CN=2)C=2C=C3C(F)(F)C4=CC(=CC=C4C3=CC=2)C=2C=C3NC(=NC3=CC=2)[C@H]2N([C@@H]3CC[C@H]2C3)C(=O)[C@@H](NC(=O)OC)C(C)C)CC21CC2 VRTWBAAJJOHBQU-KMWAZVGDSA-N 0.000 description 1
- 229960002461 ledipasvir Drugs 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical group CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- FHCUMDQMBHQXKK-CDIODLITSA-N velpatasvir Chemical compound C1([C@@H](NC(=O)OC)C(=O)N2[C@@H](C[C@@H](C2)COC)C=2NC(=CN=2)C=2C=C3C(C4=CC5=CC=C6NC(=NC6=C5C=C4OC3)[C@H]3N([C@@H](C)CC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)=CC=CC=C1 FHCUMDQMBHQXKK-CDIODLITSA-N 0.000 description 1
- 229960000863 velpatasvir Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
Definitions
- the invention relates to the field of medicinal chemistry, in particular to a preparation method of a phosphoramide compound.
- Hepatitis C virus (HCV) infection is a worldwide epidemic. There are more than 200 million chronically infected people worldwide. The chronic infection rate in Egypt is 15%, Pakistan is 4.8%, and China is 3.2%, ranking among the top three in the world.
- the clinical manifestations of hepatitis C virus infection are diverse, ranging from inflammation to severe cirrhosis and liver cancer.
- Chronic hepatitis C can also be complicated by certain extrahepatic manifestations, including rheumatoid arthritis, conjunctival keratitis sicca, lichen planus, glomerulonephritis, mixed cryoglobulinemia, B-cell lymphoma, and late onset Skin porphyria, etc., may be caused by the body's abnormal immune response.
- liver cirrhosis when hepatitis C liver cirrhosis is decompensated, various complications can occur, such as ascites and abdominal cavity infection, upper gastrointestinal bleeding, hepatic encephalopathy, hepatorenal syndrome, liver failure and other manifestations.
- Sofosbuvir English name Sofosbuvir, is a breakthrough drug developed by Gilead Sciences for the treatment of chronic hepatitis C. It was approved by the U.S. Food and Drug Administration in December 2013 and listed in the United States in January 2014. It was approved by the European Drug Administration in January 2014. The Bureau approved the listing in the European Union. Sofosbuvir alone or in combination (in combination with Ledipasvir or Velpatasvir) can treat all-genotype hepatitis C, with a cure rate of more than 95%.
- Patent application CN109689065A discloses a method for obtaining compound II by grinding intermediate compound I in a mixed solution of ethyl acetate/hexane containing pentafluorophenol, triethylamine and dimethylaminopyridine in the presence of pentafluorophenol, triethylamine and dimethylaminopyridine. The yield About 46.7%.
- Patent application CN109689672A discloses a method for preparing compound I to obtain compound II by using heptane/EtOAc as the beating solvent, and the one-step yield is only 3.57%.
- the prior art usually uses mixed organic solvents as the beating solvent to prepare compound II, but this type of method has low yield and high cost, which is not conducive to industrial production. Therefore, it is urgent to find a method that can prepare compound II with high purity and high yield. Methods.
- the present invention aims to provide an improved method for synthesizing isopropyl ((S)-(perfluorophenoxy (phenoxy) phosphoryl)-L-alanine).
- the present invention provides a method for preparing isopropyl((S)-(perfluorophenoxy(phenoxy)phosphoryl)-L-alanine), the route is as follows:
- the compound I is added to the aqueous alkali solution, stirred, and filtered to obtain the compound II, wherein the alkali is sodium bicarbonate.
- the stirring is performed at a low temperature, and the temperature is controlled at 1-10°C; preferably 2-4°C.
- the rotation speed of the stirring is 200-300 revolutions per minute; preferably 250-300 revolutions per minute.
- the pH value of the aqueous alkali solution is 8-10; preferably, the pH value is 8-9.
- the volume-to-mass ratio of the aqueous sodium bicarbonate solution to compound I is 3-5:1; preferably 4:1.
- the preparation route of Compound I is as follows:
- the preparation method of the compound I is: mixing L-alanine isopropyl hydrochloride and dichloromethane, adding phenyl dichlorophosphate, and adding triethylamine dropwise. After stirring for 3 hours, the dichloromethane solution of pentafluorophenol and triethylamine was added dropwise. After the reaction was completed, dichloromethane and water were added, stirred and separated, collected the organic phase, and concentrated under reduced pressure to obtain a solid.
- volume-mass ratio refers to the ratio of the volume of the solution in milliliters to the mass of solids in grams. For example, if the volume of a saturated sodium bicarbonate aqueous solution is 30 ml, and the mass of compound I is 10 g, it is saturated The volume-to-mass ratio of sodium bicarbonate aqueous solution and compound I is 3:1.
- the raw materials and reagents used in this example are all analytically pure, and each product has been analyzed and confirmed by hydrogen NMR spectroscopy.
- HPLC detection conditions are as follows:
- Chromatographic column octadecyl silane bonded silica gel as filler.
- Mobile phase A potassium dihydrogen phosphate solution (adjust the pH to 3.0 with phosphoric acid)-acetonitrile (90:10).
- Injection volume 20 ⁇ L.
- the inventor unexpectedly discovered that selecting a specific pH value and a specific volume-to-mass ratio NaHCO 3 aqueous solution as the solvent for beating, and controlling the temperature and stirring speed during beating can produce compounds with high yield and high purity. II.
- the reaction system does not require organic solvents, reducing the discharge of a large amount of organic solvent waste liquid, and the process is environmentally friendly, green and pollution-free.
Abstract
Provided is a preparation method for a phosphamide compound used for synthesizing a chiral drug. Compound II can be prepared with a high yield and a high purity by means of using an NaHCO3 aqueous solution with a specific pH value and a specific volume-mass ratio as a solvent for pulping and controlling the temperature and stirring speed during pulping. When said reaction system is used, an organic solvent is not required, and thus the emission of a large amount of organic solvent waste liquid is reduced and the process is environmentally friendly, green, and free of pollution.
Description
本发明涉及药物化学领域，具体为一种磷酰胺化合物的制备方法。The invention relates to the field of medicinal chemistry, in particular to a preparation method of a phosphoramide compound.
丙型肝炎病毒(HCV)感染是世界范围内流行的疾病，全球慢性感染者已超过2亿，埃及的慢性感染率为15％，巴基斯坦为4.8％，中国为3.2％，位列世界前三。丙型肝炎病毒感染的临床表现多样，轻至炎症，重至肝硬化、肝癌。慢性丙型肝炎还可以并发某些肝外表现，包括类风湿性关节炎、干燥性结膜角膜炎、扁平苔藓、肾小球肾炎、混合型冷球蛋白血症、B细胞淋巴瘤和迟发性皮肤卟啉症等，可能是机体异常免疫反应所致。且丙肝肝硬化失代偿期时，可以出现各种并发症，如腹水腹腔感染、上消化道出血、肝性脑病、肝肾综合征、肝衰竭等表现。Hepatitis C virus (HCV) infection is a worldwide epidemic. There are more than 200 million chronically infected people worldwide. The chronic infection rate in Egypt is 15%, Pakistan is 4.8%, and China is 3.2%, ranking among the top three in the world. The clinical manifestations of hepatitis C virus infection are diverse, ranging from inflammation to severe cirrhosis and liver cancer. Chronic hepatitis C can also be complicated by certain extrahepatic manifestations, including rheumatoid arthritis, conjunctival keratitis sicca, lichen planus, glomerulonephritis, mixed cryoglobulinemia, B-cell lymphoma, and late onset Skin porphyria, etc., may be caused by the body's abnormal immune response. And when hepatitis C liver cirrhosis is decompensated, various complications can occur, such as ascites and abdominal cavity infection, upper gastrointestinal bleeding, hepatic encephalopathy, hepatorenal syndrome, liver failure and other manifestations.
索磷布韦，英文名为Sofosbuvir，是吉利德科学公司开发用于治疗慢性丙型肝炎的突破性药物，2013年12月经美国食品药品监督管理局批准在美国上市，2014年1月经欧洲药品管理局批准在欧盟上市。索非布韦单独使用或复方(联合Ledipasvir或Velpatasvir)能治疗全基因型丙肝，治愈率在95％以上。Sofosbuvir, English name Sofosbuvir, is a breakthrough drug developed by Gilead Sciences for the treatment of chronic hepatitis C. It was approved by the U.S. Food and Drug Administration in December 2013 and listed in the United States in January 2014. It was approved by the European Drug Administration in January 2014. The Bureau approved the listing in the European Union. Sofosbuvir alone or in combination (in combination with Ledipasvir or Velpatasvir) can treat all-genotype hepatitis C, with a cure rate of more than 95%.
索磷布韦的合成工艺中，工业上常用的制备方法涉及将中间体I(RS-P)转化为中间体II(S-P)的步骤，具体反应如下：In the synthesis process of sofosbuvir, the commonly used industrial preparation method involves the step of converting intermediate I (RS-P) into intermediate II (S-P), and the specific reaction is as follows:
专利申请CN109689065A公开了一种采用中间体化合物I在含有五氟苯酚、三乙胺和二甲基氨基吡啶存在的乙酸乙酯/己烷的混合溶液中研磨，得到化合物II的方法，其收率约为46.7％。专利申请CN109689672A公开了一种采用庚烷/EtOAc作为打浆溶剂，将化合物I制备得到化合物II的方法，其一步收率仅仅 为3.57％。Patent application CN109689065A discloses a method for obtaining compound II by grinding intermediate compound I in a mixed solution of ethyl acetate/hexane containing pentafluorophenol, triethylamine and dimethylaminopyridine in the presence of pentafluorophenol, triethylamine and dimethylaminopyridine. The yield About 46.7%. Patent application CN109689672A discloses a method for preparing compound I to obtain compound II by using heptane/EtOAc as the beating solvent, and the one-step yield is only 3.57%.
现有技术通常采用混合有机溶剂作为打浆溶剂制备化合物II，但这类方法收率较低，成本较高，不利于工业化生产，因此，急需寻找一种能够以高纯度、高收率制备化合物II的方法。The prior art usually uses mixed organic solvents as the beating solvent to prepare compound II, but this type of method has low yield and high cost, which is not conducive to industrial production. Therefore, it is urgent to find a method that can prepare compound II with high purity and high yield. Methods.
发明内容Summary of the invention
本发明旨在提供一种改进的异丙基((S)-(全氟苯氧基(苯氧基)磷酰基)-L-丙氨酸的合成方法。The present invention aims to provide an improved method for synthesizing isopropyl ((S)-(perfluorophenoxy (phenoxy) phosphoryl)-L-alanine).
一方面，本发明提供了一种异丙基((S)-(全氟苯氧基(苯氧基)磷酰基)-L-丙氨酸的制备方法，路线如下：In one aspect, the present invention provides a method for preparing isopropyl((S)-(perfluorophenoxy(phenoxy)phosphoryl)-L-alanine), the route is as follows:
将化合物I加入至碱水溶液中搅拌，过滤得到化合物II，其中碱为碳酸氢钠。The compound I is added to the aqueous alkali solution, stirred, and filtered to obtain the compound II, wherein the alkali is sodium bicarbonate.
在一些实施方案中，所述搅拌在低温下进行，温度控制在1-10℃；优选为2-4℃。In some embodiments, the stirring is performed at a low temperature, and the temperature is controlled at 1-10°C; preferably 2-4°C.
在一些实施方案中，所述搅拌的转速为每分钟200-300转；优选为每分钟250-300转。In some embodiments, the rotation speed of the stirring is 200-300 revolutions per minute; preferably 250-300 revolutions per minute.
在一些实施方案中，所述碱水溶液的pH值为8-10；优选的，pH值为8-9。In some embodiments, the pH value of the aqueous alkali solution is 8-10; preferably, the pH value is 8-9.
在一些实施方案中，所述碳酸氢钠水溶液与化合物I的体积质量比为3-5:1；优选为4:1。In some embodiments, the volume-to-mass ratio of the aqueous sodium bicarbonate solution to compound I is 3-5:1; preferably 4:1.
在一些实施方案中，所述化合物I的制备路线如下：In some embodiments, the preparation route of Compound I is as follows:
在一些实施方案中，所述化合物I制备方法为：将L-丙氨酸异丙盐酸盐和二氯甲烷混合，加入二氯磷酸苯酯，滴加三乙胺。滴毕搅拌3h，滴加五氟苯酚和三乙胺的二氯甲烷溶液，待反应结束后，加入二氯甲烷和水，搅拌分液，收集有机相，减压浓缩，得固体。In some embodiments, the preparation method of the compound I is: mixing L-alanine isopropyl hydrochloride and dichloromethane, adding phenyl dichlorophosphate, and adding triethylamine dropwise. After stirring for 3 hours, the dichloromethane solution of pentafluorophenol and triethylamine was added dropwise. After the reaction was completed, dichloromethane and water were added, stirred and separated, collected the organic phase, and concentrated under reduced pressure to obtain a solid.
本发明中术语“体积质量比”为以毫升为单位的溶液的体积与以克为单位的固体的质量之比，例如饱和碳酸氢钠水溶液的体积为30ml，化合物I的质量为10g，则饱和碳酸氢钠水溶液与化合物I的体积质量比3:1。In the present invention, the term "volume-mass ratio" refers to the ratio of the volume of the solution in milliliters to the mass of solids in grams. For example, if the volume of a saturated sodium bicarbonate aqueous solution is 30 ml, and the mass of compound I is 10 g, it is saturated The volume-to-mass ratio of sodium bicarbonate aqueous solution and compound I is 3:1.
为了便于所属领域技术人员理解本发明，以下通过具体实施例对本发明的合成路线做具体说明：In order to facilitate those skilled in the art to understand the present invention, the following specific examples illustrate the synthetic route of the present invention:
本实施例所用的原料试剂均为分析纯，各产物均经核磁氢谱解析确认。The raw materials and reagents used in this example are all analytically pure, and each product has been analyzed and confirmed by hydrogen NMR spectroscopy.
HPLC检测条件如下：The HPLC detection conditions are as follows:
色谱柱：十八烷基硅烷键合硅胶为填充剂。Chromatographic column: octadecyl silane bonded silica gel as filler.
流动相A：磷酸二氢钾溶液(用磷酸调pH值至3.0)-乙腈(90:10)。Mobile phase A: potassium dihydrogen phosphate solution (adjust the pH to 3.0 with phosphoric acid)-acetonitrile (90:10).
流动相B：甲醇-乙腈(60:40)。Mobile phase B: methanol-acetonitrile (60:40).
线性梯度洗脱，洗脱程序如下表1：Linear gradient elution, the elution procedure is shown in Table 1:
表1Table 1
流速：1.0ml/min。Flow rate: 1.0ml/min.
柱温：40℃。Column temperature: 40°C.
波长：210nm。Wavelength: 210nm.
进样量：20μL。Injection volume: 20μL.
制备例1 化合物I的制备：Preparation Example 1 Preparation of Compound I:
将L-丙氨酸异丙盐酸盐20g和二氯甲烷100ml混合，控制温度小于-50℃，加入二氯磷酸苯酯25g。控制温度在-60℃～-50℃，滴加三乙胺24g。滴毕保温搅拌3h，控制温度-60℃～-50℃下滴加五氟苯酚和三乙胺的二氯甲烷溶液(0℃～10℃下，将五氟苯酚22g溶于二氯甲烷20ml，滴加三乙胺12g，滴毕保温搅拌30min)。滴毕，反应2h。加入二氯甲烷100ml和水200ml，搅拌分液。收集有机相，于35℃～40℃下减压浓缩，浓缩得固体。Mix 20 g of L-alanine isopropyl hydrochloride and 100 ml of dichloromethane, control the temperature to be less than -50°C, and add 25 g of phenyl dichlorophosphate. Control the temperature at -60℃～-50℃, and add 24g triethylamine dropwise. After dripping, keep warm and stir for 3 hours, control the temperature at -60℃～-50℃, add dropwise the dichloromethane solution of pentafluorophenol and triethylamine (at 0℃～10℃, dissolve 22g of pentafluorophenol in 20ml of dichloromethane, 12g of triethylamine was added dropwise, and the mixture was kept warm and stirred for 30 minutes after the drop). After dripping, react for 2h. Add 100 ml of dichloromethane and 200 ml of water, and stir to separate the liquids. The organic phase was collected, concentrated under reduced pressure at 35°C to 40°C, and concentrated to obtain a solid.
实施例1-17 化合物II的制备：Example 1-17 Preparation of Compound II:
每次称取化合物I的固体80g，加入至碱水溶液中，控制温度及转速搅拌1h后离心，过滤，干燥，得到白色固体，即化合物II。Weigh 80g of the solid of compound I each time, add it to the alkaline aqueous solution, control the temperature and speed and stir for 1 h, centrifuge, filter, and dry to obtain a white solid, namely compound II.
具体条件及操作如下表2，计算化合物II的纯度和收率。The specific conditions and operations are shown in Table 2 below to calculate the purity and yield of compound II.
表2Table 2
通过上述一系列实施例，发明人意外的发现选取特定的pH值、特定体积质量比的NaHCO
3水溶液作为打浆的溶剂，并控制打浆时的温度、搅拌速度能以高收率、高纯度制备化合物II，同时该反应体系不需要有机溶剂，减少了大量的有机溶剂废液的排放，工艺环境友好、绿色无污染。
Through the above series of embodiments, the inventor unexpectedly discovered that selecting a specific pH value and a specific volume-to-mass ratio NaHCO 3 aqueous solution as the solvent for beating, and controlling the temperature and stirring speed during beating can produce compounds with high yield and high purity. II. At the same time, the reaction system does not require organic solvents, reducing the discharge of a large amount of organic solvent waste liquid, and the process is environmentally friendly, green and pollution-free.
以上所述，仅为本发明较佳的具体实施方式，但本发明的保护范围并不局 限于此，任何熟悉本技术领域的技术人员在本发明揭露的技术范围内，可轻易想到的变化或替换，都应涵盖在本发明的保护范围之内。因此，本发明的保护范围应以所述权利要求的保护范围为准。The above are only the preferred specific embodiments of the present invention, but the protection scope of the present invention is not limited thereto. Any person skilled in the art can easily think of changes or changes within the technical scope disclosed by the present invention. All replacements shall be covered within the protection scope of the present invention. Therefore, the protection scope of the present invention should be subject to the protection scope of the claims.
Claims (10)
- 一种异丙基((S)-(全氟苯氧基(苯氧基)磷酰基)-L-丙氨酸的制备方法，其特征在于，路线如下：A method for preparing isopropyl ((S)-(perfluorophenoxy (phenoxy) phosphoryl)-L-alanine), which is characterized in that the route is as follows:
将化合物I加入至碱水溶液中搅拌，过滤得到化合物II，其中所述碱为碳酸氢钠。Compound I is added to the aqueous alkali solution, stirred, and filtered to obtain compound II, wherein the alkali is sodium bicarbonate. - 如权利要求1所述的制备方法，其特征在于，搅拌在低温下进行，温度控制在1-10℃。The preparation method according to claim 1, wherein the stirring is carried out at a low temperature, and the temperature is controlled at 1-10°C.
- 如权利要求2所述的制备方法，其特征在于，搅拌在低温下进行，温度控制在2-4℃。The preparation method according to claim 2, wherein the stirring is carried out at a low temperature, and the temperature is controlled at 2-4°C.
- 如权利要求1所述的制备方法，其特征在于，搅拌的转速为：每分钟200-300转。The preparation method according to claim 1, wherein the rotation speed of the stirring is 200-300 revolutions per minute.
- 如权利要求4所述的制备方法，其特征在于，搅拌的转速为每分钟250转。The preparation method according to claim 4, wherein the rotation speed of the stirring is 250 revolutions per minute.
- 如权利要求1所述的制备方法，其特征在于，碱水溶液的pH值为8-10。The preparation method according to claim 1, wherein the pH of the aqueous alkali solution is 8-10.
- 如权利要求6所述的制备方法，其特征在于，碱水溶液的pH值为8-9。8. The preparation method according to claim 6, wherein the pH of the aqueous alkali solution is 8-9.
- 如权利要求1-7任一项所述的制备方法，其特征在于，碳酸氢钠水溶液与化合物I的体积质量比为3-5:1。7. The preparation method according to any one of claims 1-7, wherein the volume-to-mass ratio of the sodium bicarbonate aqueous solution to the compound I is 3-5:1.
- 如权利要求8所述的制备方法，其特征在于，碳酸氢钠水溶液与化合物I的体积质量比为4:1。8. The preparation method of claim 8, wherein the volume-to-mass ratio of the sodium bicarbonate aqueous solution to the compound I is 4:1.
- 如权利要求1所述的制备方法，其特征在于，所述化合物I是由以下路线制备得到：The preparation method of claim 1, wherein the compound I is prepared by the following route:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2020/097026 WO2021253376A1 (en) | 2020-06-19 | 2020-06-19 | Preparation method for phosphamide compound used for synthesizing chiral drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2020/097026 WO2021253376A1 (en) | 2020-06-19 | 2020-06-19 | Preparation method for phosphamide compound used for synthesizing chiral drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2021253376A1 true WO2021253376A1 (en) | 2021-12-23 |
Family
ID=79268918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2020/097026 WO2021253376A1 (en) | 2020-06-19 | 2020-06-19 | Preparation method for phosphamide compound used for synthesizing chiral drug |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2021253376A1 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018033139A1 (en) * | 2016-08-19 | 2018-02-22 | 正大天晴药业集团股份有限公司 | Preparation method for chiral phosphate ester |
| CN109689065A (en) * | 2016-06-24 | 2019-04-26 | 埃默里大学 | For treating the phosphinylidyne aminate of hepatitis type B virus |
| CN109689672A (en) * | 2016-09-07 | 2019-04-26 | 阿堤亚制药公司 | 2 '-- N replaced for RNA virus treatment6The purine nucleotides replaced |
| CN111087421A (en) * | 2019-12-24 | 2020-05-01 | 南京正大天晴制药有限公司 | Preparation method of phosphamide compound for chiral drug synthesis |
-
2020
- 2020-06-19 WO PCT/CN2020/097026 patent/WO2021253376A1/en active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109689065A (en) * | 2016-06-24 | 2019-04-26 | 埃默里大学 | For treating the phosphinylidyne aminate of hepatitis type B virus |
| WO2018033139A1 (en) * | 2016-08-19 | 2018-02-22 | 正大天晴药业集团股份有限公司 | Preparation method for chiral phosphate ester |
| CN109689672A (en) * | 2016-09-07 | 2019-04-26 | 阿堤亚制药公司 | 2 '-- N replaced for RNA virus treatment6The purine nucleotides replaced |
| CN111087421A (en) * | 2019-12-24 | 2020-05-01 | 南京正大天晴制药有限公司 | Preparation method of phosphamide compound for chiral drug synthesis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101809008B (en) | Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity and intermediate thereof | |
| CN103694230B (en) | A kind of High-purity canagliflozin compound and preparation method thereof | |
| CN104496952B (en) | Synthesis method of dapagliflozin | |
| CN102143967B (en) | Purification method for adefovir dipivoxil | |
| WO2021253376A1 (en) | Preparation method for phosphamide compound used for synthesizing chiral drug | |
| CN103342664B (en) | Method for preparing tartrate | |
| CN111087421B (en) | Preparation method of phosphamide compound for chiral drug synthesis | |
| CN110423257B (en) | Sofosbuvir synthesis process | |
| Freeman et al. | Stereoselectivity in electrophile-mediated intramolecular cyclizations of hept-2-enitols | |
| CN104326959B (en) | A kind of preparation method of Ezetimibe isomers | |
| EP3953334A1 (en) | Novel synthetic options towards the manufacture of (6r,10s)-10- {4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)- pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15 -(metheno)pyrazolo [4,3-b] [1,7] diazacyclotetradecin-5(6h)-one | |
| JPH04297490A (en) | New method of manufacturing 17beta-alkanoyl-3-oxo-4- aza-5alpha-androst-1-enes | |
| CN107488156A (en) | A kind of synthetic method of unformed glucitol | |
| CN111320664B (en) | Preparation method of 24-cholenenoic acid ethyl ester | |
| CN107868105A (en) | A kind of preparation method of Suo Feibuwei key intermediates | |
| CN107098927A (en) | The technique that a kind of crystallisation prepares high-purity egg yolk lecithin | |
| Kawashima | Four-membered heterocyclic compounds containing high coordinate group 16 elements | |
| LU83992A1 (en) | NEW FLUORPROSTACYCLINE | |
| CN106977543A (en) | The preparation technology of improved Suo Feibuwei intermediates | |
| EP0044105B1 (en) | New 8-alpha-oestra-1,3,5(10)-triene derivatives, processes for their preparation and pharmaceutical compositions | |
| CN107304194A (en) | The method for preparing Dapagliflozin | |
| CN111004300B (en) | Method for preparing Sofosbuvir | |
| CN106916181A (en) | The preparation method of vitamin D class key intermediate of medicament | |
| CN110294782B (en) | Preparation method of 11-alkene steroid compound | |
| CN102391145B (en) | Method for resolving optical isomer of ubenimex intermediate conveniently |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20940995 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 20940995 Country of ref document: EP Kind code of ref document: A1 |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 20940995 Country of ref document: EP Kind code of ref document: A1 |
|
| 32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 10/07/2023 |